VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting

Phase 1

Phase 2

VMD-928VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Sponsor:

VM Oncology, LLC

Code:

NCT03556228

Conditions

Head and Neck Carcinoma

Adenoid Cystic Carcinoma

Lung Cancer

Non-Small Cell Lung Cancer

Pancreatic Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

VMD-928 100 mg Tablet

VMD-928 Tablet and Pembrolizumab (200 mg)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-03. This information was provided to ClinicalTrials.gov by VM Oncology, LLC on 2025-12-11.